Michael Kauffman

Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

The Jones Group, Inc. designs, markets and wholesales brands with product expertise in apparel, footwear, jeanswear, jewelry and handbags. The company markets directly to consumers through its branded specialty retail and outlet stores and through its ecommerce sites. It operates through six segments: Domestic Wholesale Sportswear, Domestic Wholesale Jeanswear, Domestic Wholesale Footwear & Accessories, Domestic Retail, International Wholesale and International Retail. The Domestic Wholesale Sportswear segment's brands cover a broad array of categories for the women's markets which includes career and casual sportswear, jeanswear, dresses, suits, and a combination of all components termed lifestyle collection. The Domestic Wholesale Jeanswear segment's brands cover a broad array of categories for the women's, juniors and girls markets which includes jeanswear, casual sportswear and dresses, with a focus on fit, fabric and finish. The Domestic Wholesale Footwear & Accessories segment operations include the sale of both branded and private label footwear, handbags, small leather goods and costume, semi-precious, sterling silver, and marcasite jewelry. The Domestic Retail segment markets apparel, footwear and accessories directly to consumers through its specialty retail stores operating in malls and urban retail centers, its various value-based stores located in major retail locations, and on several e-commerce web sites that it operates. The International Wholesale segment's operations include the sale of brand-name footwear, handbags, small leather goods, jewelry and apparel to distributors and retailers outside the United States. The International Retail segment markets apparel, footwear and accessories directly to consumers through its specialty retail stores operating in malls and urban retail centers, through its various value-based stores located in major retail locations, through concessions located in department stores and a number of airports and through e-commerce websites accessible to international consumers. The company was founded by Sidney Kimmel in 1970 and is headquartered in New York, NY.

Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA.

Bessemer Venture Partners LP seeks investment opportunities in companies primarily located in the US. The fund focuses on companies with a strong business model, experienced management teams and growth potential. It targets companies operating across a broad range of sectors such as healthcare, information systems, telecommunications, and retailing. It provides financing for seed, early and later stage capital requirements.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019.

Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA.